Physician- and Patient-based Barriers to NGS Testing (NCT07209176)
A Clinical Trial to Address Physician- and Patient-based Barriers to NGS Testing
🩺 Plain-English Summary (8th-Grade Level)
The goal of this study is to improve next-generation sequencing (NGS) testing rates at Johns Hopkins in patients with metastatic prostate cancer. Investigators believe by targeting two barriers, provider-level and patient-level, will improve the testing rate of NGS at Johns Hopkins.
Who can join: To join this study, participants generally need to meet the listed inclusion criteria (2 items) and avoid the listed exclusions (1 items).
Location: Johns Hopkins Sidney Kimmel Comprehensive Cancer Center — Baltimore, Maryland
Age range: 18 Years
🧪 Interventions in This Study
- Provider-level and patient education at end of study (OTHER)
- Provider-level and patient-level (OTHER)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistCheck every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).
Usually NOT eligible if any of the following apply:
- Exclusion Criteria: \- Patients who have already had NGS testing performed.
🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.
📍 All Participating Trial Locations (1 Sites)
- Johns Hopkins Sidney Kimmel Comprehensive Cancer Center — Baltimore, Maryland
📞 Contact the Study Coordinator
Phone: (410) 955-0231
Email: chm@jhmi.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Metastatic Prostate Cancer
- 177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer — San Francisco, California
- Phase Ia/Ib Talazoparib + Tazemetostat for mCRPC — Boston, Massachusetts
- A Journey Into Participation Patterns Among Metastatic Prostate Cancer Patients — San Francisco, California
- PSMAtrack-tracking Changes in PSMA-PET During Initial Therapy for Metastatic Hormone-sensitive Prostate Cancer — Boston, Massachusetts
- TOward a comPrehensive Supportive Care Intervention for Older Men With Metastatic Prostate Cancer — Toronto, Ontario
Explore by condition: All Metastatic Prostate Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.